Assisted lead counsel in representing Biotest AG (Biotest), a German publicly traded biotechnology company, in signing a global License, Development and Commercialization Agreement with Abbott Laboratories for the further development and commercialization of Biotest’s BT-061, a novel anti-CD4 antibody for the treatment of Rheumatoid Arthritis (RA) and psoriasis. In connection with the deal, Biotest will receive an upfront payment of $85 million, and upon completion of certain milestones, additional payments totaling $395 million, plus royalties.

Experience Center

Match our Experience to Your Needs

Experience Highlights

Trademark and unfair competition matters for Diageo North America
Represents Diageo North America in a variety of trademark and unfair competition matters, including litigation in federal district court and before more
Boardman Petroleum, Inc. v. Federated Mut. Ins. Co.
The firm served as lead counsel to Boardman Petroleum in two significant actions resulting in reported decisions. The first action was brought more
Sale of pulp operations for one of the largest U.S. forest products manufacturers
Representing one of the largest U.S. forest products manufacturers in the sale of two if its Southeast pulp operations for $610 million. more
Installation of dedicated solar power facility Oldcastle Architectural Inc.
Represented Oldcastle Architectural Group concrete-manufacturing facility in negotiations with independent power producer regarding proposed more